| 臺大學術典藏 |
2018-09-10T07:26:51Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, C.-J. and Lee, P.-H. and Lin, D.-Y. and Wu, C.-C. and Jeng, L.-B. and Lin, P.-W. and Mok, K.-T. and Lee, W.-C. and Yeh, H.-Z. and Ho, M.-C. and Yang, S.-S. and Lee, C.-C. and Yu, M.-C. and Hu, R.-H. and Peng, C.-Y. and Lai, K.-L. and Chang, S.S.-C. and Chen, P.-J.; 劉俊人;李伯皇;胡瑞恆;吳誠中;鄭隆賓;林炳文;莫景棠;葉宏仁;何明志;楊勝舜;陳培哲; LIU, CHUN-JEN;LEE, PO-HUANG;HU, REY-HENG;WU, CHENG-CHUNG;JENG, LONG-BIN;LIN, PIN-WEN;MOK, KING-TONG;YEH, HONG-ZEN;HO, MING-CHIH;YANG, SHENG-SHUN;CHEN, PEI-JER; MING-CHIH HO; PO-HUANG LEE; CHUN-JEN LIU; PEI-JER CHEN; REY-HENG HU; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 國立臺灣大學 |
2009 |
Heparanase Inhibitor Pi-88 as Adjuvant Therapy for Hepatocellular Carcinoma after Curative Resection: A Randomized Phase Ii Trial for Safety and Optimal Dosage
|
劉俊人; 李伯皇; 胡瑞恆; 吳誠中; 鄭隆賓; 林炳文; 莫景棠; 葉宏仁; 何明志; 楊勝舜; 陳培哲; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
